What Is Zepbound?

1. What is Zepbound approved for?

Two indications, each from its own trial program. The first, from November 2023, is to reduce excess body weight and maintain the reduction long term in adults with obesity (BMI 30 or above) or with overweight (BMI 27 or above) plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. The second, from December 2024, is moderate to severe obstructive sleep apnea in adults with obesity, which made Zepbound the first drug approved for the condition.

Zepbound has no diabetes, cardiovascular, or liver indication. Its sibling Mounjaro carries the type 2 diabetes and cardiovascular indications for the same molecule, and the Zepbound vs Mounjaro page explains why one drug has two labels. Among the weight-loss brands, Wegovy has the cardiovascular and MASH indications Zepbound lacks; Zepbound has the sleep apnea indication Wegovy lacks.

2. What is the Zepbound dose schedule?

The label starts every patient at 2.5 mg once weekly for 4 weeks, a dose it describes as for treatment initiation rather than effect, then increases in 2.5 mg increments after at least 4 weeks on the current dose.

The ladder moves by tolerability, not calendar. If a step is not tolerated, the label allows delaying the next increase, and a prescriber may keep someone at 5 or 10 mg indefinitely. The titration schedule tool dates the steps from a chosen start day.

Missed dose. Take it as soon as possible within 4 days (96 hours). Past that, skip it and resume on the regular day. Never inject two doses within 3 days of each other. The day of the week can be changed as long as the two doses are at least 3 days (72 hours) apart. The missed-dose tool applies the rule to a date.

Injection. Under the skin of the abdomen, thigh, or back of the upper arm, rotating sites each dose, any time of day, with or without food.

3. How much weight do people lose on Zepbound?

SURMOUNT-1 is the pivotal trial: 2,539 adults with obesity or overweight and no diabetes, randomised to 5, 10, or 15 mg or placebo for 72 weeks.

SURMOUNT-4 is the trial to read alongside the headline. It withdrew the drug after 36 weeks: 89.5% of those who continued kept at least 80% of their loss, against 16.6% of those switched to placebo. The label’s indication includes maintaining the reduction long term for that reason. The SURMOUNT-1 body-composition substudy found about 75% of the weight lost was fat and 25% lean mass, the same split as placebo; the muscle loss page covers what that does and does not mean.

4. What did the sleep apnea trials show?

SURMOUNT-OSA ran two 52-week trials in adults with moderate to severe obstructive sleep apnea and obesity, one in people not using positive airway pressure and one in people already on it. The endpoint was the apnea-hypopnea index, the number of breathing interruptions per hour of sleep.

The FDA noted the improvement was likely related to the weight loss itself. The label’s maintenance doses for the indication are 10 or 15 mg.

5. Pens or vials?

The label lists four presentations. Single-dose pens and single-dose vials each deliver one 0.5 mL dose, available across all six strengths (2.5 through 15 mg). Multi-dose vials and single-patient-use KwikPens each hold 4 doses, delivering 0.6 mL per injection at the corresponding strength. The molecule and the milligrams per dose are the same across presentations; the difference is the device and how many doses it holds. Before injecting, the label says to check that the solution is clear and colorless to slightly yellow, and not to use it if it looks cloudy, discolored, or contains particles.

A vial dose is prescribed in milligrams but drawn in millilitres. The dose calculator does the conversion, and the log entry is the same either way: product, date, milligrams, and injection site. There is no tirzepatide tablet; Lilly’s oral GLP-1 is a different molecule, orforglipron.

Storage. Zepbound is stored refrigerated at 2°C to 8°C (36°F to 46°F) before first use. It ships in a manufacturer cold-chain package; the pen, syringe, or vial should go into the refrigerator promptly and stay in its original carton, protected from light, until use.

6. What about type 2 diabetes and weight loss together?

Zepbound itself has no diabetes indication, but the SURMOUNT-2 trial tested tirzepatide for weight reduction specifically in adults with obesity and type 2 diabetes, the population most GLP-1 weight trials exclude. Over 72 weeks, 10 mg produced 12.8% mean weight loss and 15 mg produced 14.7%, against 3.2% on placebo, smaller than the non-diabetes SURMOUNT-1 results but still far ahead of placebo. Between 79% and 83% of the tirzepatide groups lost at least 5% of body weight, against 32% on placebo. This is the same molecule sold as Mounjaro for glycemic control; the SURMOUNT-2 population shows what the weight effect looks like when diabetes is also present.

7. Who should not take it, and what else does the label cover?

The label states that safety and effectiveness have not been established in pediatric patients, so Zepbound is limited to adults. No dose adjustment is recommended for renal or hepatic impairment. For pregnancy, the label says weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises stopping Zepbound once a pregnancy is recognized. For breastfeeding, the label asks a prescriber to weigh the benefits of breastfeeding against the mother’s need for the drug and any potential effect on the infant. Before injecting, check that the solution is clear and colorless to slightly yellow; discard it if particles or discoloration are visible.

8. What are the side effects and warnings?

The label opens with a boxed warning on thyroid C-cell tumors, seen in rats, with a contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2. The warnings and precautions cover severe gastrointestinal reactions, acute kidney injury from dehydration, acute gallbladder disease, acute pancreatitis, hypersensitivity, hypoglycemia when combined with insulin or a sulfonylurea, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration under anesthesia.

Most of it happens during dose escalation, which is why the ladder holds each step at least 4 weeks. Zepbound’s label tells people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase, because delayed gastric emptying can reduce absorption of the pill. Semaglutide’s labels carry no such line. Foundayo (orforglipron), Lilly’s oral GLP-1, has its own version of this precaution in its label.

9. How do you track Zepbound?

Because the half-life is about 5 days, each weekly dose overlaps the last, and steady state arrives after about 4 weeks on a given step. A log that records the step, the date, and the site shows where the ladder stands and whether a missed dose fell inside the 4-day window. The half-life visualizer draws the curve, and how GLP-1 tracking works covers what to record.

“Zepbound” names the FDA-approved brand and its label; “tirzepatide” names the molecule itself, which is also the active ingredient in Mounjaro. The brand identifies the product and its FDA-approved indications; the molecule name identifies the active ingredient. The tirzepatide molecule page covers the pharmacology shared by both brands.

10. What Is Zepbound FAQ

• How much weight do people lose on Zepbound?

  In SURMOUNT-1, adults with obesity and no diabetes lost 15.0%, 19.5%, and 20.9% of body weight on 5, 10, and 15 mg over 72 weeks, against 3.1% on placebo. 57% of the 15 mg group lost at least 20%. In SURMOUNT-5, the head-to-head with Wegovy, tirzepatide produced 20.2% versus 13.7% at 72 weeks.

• What is the Zepbound dosing schedule?

  Start at 2.5 mg once weekly for 4 weeks. Then increase in 2.5 mg steps, holding each step at least 4 weeks: 5, 7.5, 10, 12.5, and 15 mg. The label's maintenance doses are 5, 10, or 15 mg for weight reduction and 10 or 15 mg for obstructive sleep apnea. 15 mg is the maximum. A prescriber may hold a step longer if it is not tolerated.

• What if I miss a dose of Zepbound?

  The label says to take it as soon as possible within 4 days (96 hours) of the missed dose. After 4 days, skip it and take the next dose on the regular day. Never take two doses within 3 days of each other. The injection day can be changed as long as the two doses are at least 3 days (72 hours) apart.

• Is Zepbound the same as Mounjaro?

  Same molecule, same doses, same devices, different label. Mounjaro is approved for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes; Zepbound is approved for weight reduction and obstructive sleep apnea. The Zepbound vs Mounjaro page sets the two labels side by side.

• Does Zepbound come in vials?

  Yes. The label lists single-dose pens and single-dose vials, each delivering 0.5 mL per dose across all six strengths, plus multi-dose vials and single-patient-use KwikPens that each hold 4 doses and deliver 0.6 mL per dose. A vial dose is prescribed in milligrams and drawn in millilitres; the dose calculator does the conversion.

• What are the side effects of Zepbound?

  In the label's pooled trials, nausea occurred in 28% on 15 mg versus 8% on placebo, diarrhea 23% versus 8%, vomiting 13% versus 2%, and constipation 11% versus 5%, mostly during dose escalation. The boxed warning is thyroid C-cell tumors seen in rats; the label also warns on pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury from dehydration, hypoglycemia with insulin or sulfonylureas, and reduced absorption of oral contraceptives. Zepbound's label carries this contraception instruction; semaglutide's labels do not, though Foundayo (orforglipron) has its own version of it.

• Does Zepbound work for people with type 2 diabetes?

  Zepbound has no diabetes indication, but the SURMOUNT-2 trial tested tirzepatide for weight loss in adults with obesity and type 2 diabetes: 12.8% mean weight loss on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo. Adults wanting glycemic control specifically should discuss Mounjaro, tirzepatide's diabetes-labeled sibling, with a prescriber.

• Can Zepbound be used during pregnancy or breastfeeding?

  No. The label states weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises discontinuing Zepbound once a pregnancy is recognized. For breastfeeding, a prescriber weighs the benefits of breastfeeding against the mother's clinical need for the drug. The label also has not established safety in pediatric patients, and no dose adjustment is recommended for renal or hepatic impairment.

11. Sources